Compare Procter & Gamble Co (PG) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Procter & Gamble Co vs ResMed Inc. — how do they compare? Procter & Gamble Co trades at $151.06 (market cap $349.77B), while ResMed Inc. trades at $229.48 (market cap $31.89B). The key difference: Procter & Gamble Co is far larger — about 11× ResMed Inc.'s market cap, and Procter & Gamble Co pays the higher dividend (2.89%). Which is the better fit depends on your goals — on Pluang, investors hold Procter & Gamble Co for 131 Days and ResMed Inc. for 51 Days on average.
| PG | RMD | |
|---|---|---|
Market Cap | $349.77B | $31.89B |
Volume | 10,055,825 | 618,314 |
Sector | Consumer Staples | Health |
52-Week High | $167.18 | $277.88 |
52-Week Low | $138.10 | $182.82 |
Typical Hold Time | 131 Days | 51 Days |
Enterprise Value | $375.61B | $31.24B |
Dividend Yield | 2.89% | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Procter & Gamble (PG) trades at $147.82, down 0.4% on the day, showing resilience amid market volatility. The stock maintains a bullish technical signal with strong moving average support and has consistently beaten earnings estimates in recent quarters. PG demonstrates robust fundamentals with $84.28B revenue, 18.44% net margin, and steady dividend payments, though valuation multiples remain elevated versus peers.
PG offers stable growth with dividend reliability but faces premium valuation concerns. The 8.3% upside to consensus target of $160.13 suggests moderate potential, while competitive pressures and soft demand outlook present headwinds. Institutional ownership trends show mixed positioning, requiring careful monitoring of margin sustainability and consumer spending patterns.
ResMed (RMD) trades at $228.37, up 1.06% today, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15B in 2025, with a robust net income margin of 26.94%. Recent news highlights management's presentation at the Morgan Stanley Healthcare Conference and an upcoming Q1 2027 earnings report.
The outlook is positive, supported by earnings growth targets of 12-14% and a consensus price target of $242.70. Key risks include competitive pressures and ongoing legal investigations. Institutional buying activity and analyst upgrades reflect confidence, but investors should monitor execution against growth targets and any developments from the legal probe.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
